Site icon OncologyTube

Mirvetuximab soravtansin side effects compared to other systemic treatments in heavily pretreated OC #SGOMTG

Michael J. Birrer, MD of Massachusetts General Hospital discusses mirvetuximab soravtansin side effects compared to other systemic treatments in heavily pretreated OC at SGO 2016.

Transcription:

Ameritech some have survey and seeing is a antibody drug kanji and by definition these are drugs he’s our agency does specifically to the tumor. The distribution of fully receptor alpha in ovarian cancer patients is as almost solely locator on the. I cancer cells there’s a low level expression in the kidney tubules and some expression on type two alveolar cells begin see right there is extremely selective. So the side effects are minimal I in my view there is some diarrhea that usually grade one or grade two easily controllable with Imodium we rarely have to use low modal and there is a unique visual a toxicity which involves a keratitis in the cornea where Microsoft’s form mechanism is not completely cleared Stephanie secondary to drug it’s completely reversible usually develops in the second week of the second cycle which we think is related to the corneal epithelial cells. Overall the I consider taxes he says you do drug to be much better than the standard of care options like voxel weekly taxol Jim citing.

Exit mobile version